Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from Globe Newswire

10:57 EDT 22nd July 2018 | BioPortfolio

Here are the most relevant search results for "Globe Newswire" found in our extensive news archives from over 250 global news sources.

More Information about Globe Newswire on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Globe Newswire for you to read. Along with our medical data and news we also list Globe Newswire Clinical Trials, which are updated daily. BioPortfolio also has a large database of Globe Newswire Companies for you to search.

Showing News Articles 1–25 of 25,000+ from Globe Newswire

Thursday 19th July 2018

Arcturus Therapeutics Announces Annual and Extraordinary General Meeting of Shareholders to Be Held on August 24, 2018

SAN DIEGO, July 20, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (“Arcturus” or the “Company”) (NASDAQ:ARCT), an RNA medicines company, today announced that it will hold an Annual and Extraordinary General Meeting of Shareholders (or the “Meeting”), on Friday, August 24, 2018, at 10:00 am (Pacific Time), at 4655 Executive Drive, Suite 700, San Diego, CA 92121, for the followi...

Crinetics Pharmaceuticals Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

SAN DIEGO, July 20, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq:CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the closing of its initial public offering of 6,900,000 shares of common stock, which includes the exercise i...

Collegium to Host Conference Call to Discuss Second Quarter 2018 Financial Results and Provide Corporate Update

CANTON, Mass., July 20, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, August 8, 2018 at 4:30 p.m. Eastern Time.  The Company will discuss its financial results and provide a corporate update. Conference Call Information:  To access the conference call, please dial (...

Poseida Awarded $3.99 Million CIRM Grant to Support Preclinical Development of P-PSMA-101, a T Stem Cell Memory CAR-T Therapy for Prostate Cancer

SAN DIEGO, July 20, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based clinical-stage company translating best-in-class gene engineering technologies into lifesaving cell therapies, today announced that the California Institute for Regenerative Medicine (CIRM) awarded a $3.99 million CLIN 1 grant to support the late stage preclinical development of Poseida’s...

FDA Grants Approval of TIBSOVO®, the First Oral, Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 Mutation

CAMBRIDGE, Mass., July 20, 2018 (GLOBE NEWSWIRE) -- - Approval of TIBSOVO® was Based on Phase 1 Study Results, Including Rate and Duration of Complete Remission (CR) and CR with Partial Hematologic Recovery (CRh) and Rate of Conversion to Transfusion Independence1 -

Biogen to Host Investor Webcast to Discuss Alzheimer’s Disease Portfolio on July 25, 2018

CAMBRIDGE, Mass., July 20, 2018 (GLOBE NEWSWIRE) -- Biogen (Nasdaq:BIIB) today announced it will host a live webcast providing a Q&A session related to its Alzheimer’s disease investigational therapies on Wednesday, July 25, 2018.  The live webcast will begin at 6:00 p.m. ET/5:00 p.m. CT on July 25, 2018, with Alfred Sandrock, Jr., M.D., Ph.D., executive vice president and chief medical ...

SELLAS Receives Fast Track Designation from FDA for Galinpepimut-S for the Treatment of Patients with Multiple Myeloma

NEW YORK, July 20, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group Inc. (Nasdaq:SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company’s lead asse...

Arch Therapeutics Appoints Healthcare Industry Executive Punit Dhillon to Board of Directors

FRAMINGHAM, Mass., July 20, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) (“Arch” or the “Company”), developer of the AC5 Surgical Hemostatic Device™ (“AC5™”), today announced the appointment of Punit Dhillon, former President & CEO of OncoSec Medical, Inc. (NASDAQ:ONCS), to its Board of Directors (the “Board”) as an independent member effective as of Jul...

T2 Biosystems Announces 2018 Second Quarter Financial and Operational Results Release and Conference Call Date

LEXINGTON, Mass., July 20, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, today announced that it will release its 2018 second quarter financial and operational results after the market closes on Thursday, August 2, 2018. In conjunction with ...

Enochian Biosciences Announces Appointment of Dr. David Hardy to Scientific Advisory Board

LOS ANGELES, July 20, 2018 (GLOBE NEWSWIRE) -- Enochian Biosciences, Inc. (“Enochian”) (OTCQB:ENOB), a biopharmaceutical company focused on the development and commercialization of novel therapies for HIV/AIDS and cancer, announced today the appointment of David Hardy, MD, to its Scientific Advisory Board (SAB).  Dr. W. David Hardy currently serves as Senior Director of Evidence-bas...

BeiGene Attends Hearing Before the Listing Committee of the Stock Exchange of Hong Kong Limited

CAMBRIDGE, Mass. and BEIJING, China, July 20, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that it attended a hearing before the Listing Committee of the Stock Exchange of Hong Kong Limited (“HKEx...

Wednesday 18th July 2018

Repligen to Report Second Quarter 2018 Financial Results

WALTHAM, Mass., July 19, 2018 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter of 2018 financial results on Thursday, August 2, 2018. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the three- and six-month re...

CFN Media: Koios Expands into Cannabis Functional Beverages

SEATTLE, July 19, 2018 (GLOBE NEWSWIRE) -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Koios Beverage Corp (CSE:KBEV) (OTC:SNOVF) and their expansion into Cannabis Functional Beverages. The cannabis industry is projected to reach $50 billion by 2026, acco...

BioStem Technologies (BSEM) Subsidiary Nesvik Pharmaceuticals Announces the Completion of An Asset Purchase of Multiple New Drug Compounds and Launches Joint Development Venture with CCM Pharma Solutions

Pompano Beach, FL, July 19, 2018 (GLOBE NEWSWIRE) -- Nesvik Pharmaceuticals (f/k/a BioStem Pharmaceuticals), a subsidiary of BioStem Technologies, Inc. (OTC PINK: BSEM) (“BioStem” or the “Company”), a global life sciences corporation, is pleased to announce the Asset Purchase of multiple New Drug Compounds from CCM Pharma Solutions establishing the beginning of a Joint Venture. ...

Oncobiologics Completes Exchange of Series A Convertible Preferred Stock for Newly Created Series A-1 Convertible Preferred Stock

CRANBURY, N.J., July 19, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (Nasdaq:ONS) today announced that, on July 18, 2018, the Company completed the exchange of an aggregate of 58,735 shares of voting Series A Convertible Preferred Stock (the “Series A”) held by GMS Tenshi Holdings Pte. Limited (“GMS Tenshi”), a Singapore private limited company and the Company’s controlling stockhold...

Golden Leaf Holdings Provides Progress Update for Medical Marijuana Group

TORONTO, July 19, 2018 (GLOBE NEWSWIRE) -- Golden Leaf Holdings Ltd. (“Golden Leaf” or the “Company”) (CSE:GLH) (OTCQB:GLDFF), a cannabis company with cultivation, production and retail operations built around recognized brands, is pleased to provide a progress update for Medical Marijuana Group (“MMG”), its Canadian subsidiary. Cultivation Activities Update In November 2017,...

Harvard Bioscience Schedules Second Quarter 2018 Conference Call for July 26 at 4:30 PM ET

HOLLISTON, Mass., July 19, 2018 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will announce results for its second quarter 2018 after market trading hours on Thursday, July 26, 2018. A conference call to discuss the company's second quarter 2018 financial results and its operations...

Interpace Diagnostics Expands Application of Pancreatic Cancer Test

PARSIPPANY, N.J., July 19, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (the “Company” or “Interpace Diagnostics”), a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and management, announced today that the Company has expanded the applicati...

Arbutus to Report Second Quarter 2018 Financial Results

WARMINSTER, Pa., July 19, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its second quarter financial results, conference call and webcast for Thursday, August 2, 2018. The schedule for the press release and conference call/webcast are as follows: •Q2 2018 P...

Mustang Bio Completes Pre-IND Meeting with FDA for MB-102 (CD123 CAR T)

NEW YORK, July 19, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology, announced today that it has completed a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administrat...

International Endeavors Corp. (IDVV) Reports Canadian Interest is Greater than Expected

TEMECULA, Calif., July 19, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- International Endeavors Corporation (OTC stock symbol: IDVV) manufacturer the Off-Grid Grow Laboratory (OGGL) for licensed marijuana growers, reports on the market conditions in Canada. Currently, Health Canada says there are 113 licenses for marijuana cultivation operations in the entire country. 61 of the licenses are ...

Poseida Therapeutics Appoints John P. Schmid to Board of Directors

SAN DIEGO, July 19, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies, today announced the appointment of John P. Schmid to the Company’s Board of Directors. “John brings a wealth of leadership, corporate finance, and audit committee experience to Poseida through his prior ro...

Women In Bio Announces Completion of the 2018 Boardroom Ready Selection Process

NEW YORK, July 19, 2018 (GLOBE NEWSWIRE) -- Women In Bio (WIB), an organization of professionals committed to promoting careers, leadership, and entrepreneurship of women in the life sciences, is pleased to announce that Boardroom Ready has selected 20 highly qualified women to participate in the 2018 program. Launched in 2016, Boardroom Ready is Executive Women In Bio’s (EWIB) exclusive exe...

Progressive Care Signs Two New 340B Contracts to Bring Discounted Prescription Programs to Non-Profit Healthcare Institutions

MIAMI, July 19, 2018 (GLOBE NEWSWIRE) -- Progressive Care Inc. (OTCQB:RXMD), a personalized healthcare services and technology company, today announced that they have signed two new 340B contracts, furthering their commitment to providing non-profit or charitable healthcare institutions with significantly reduced prices on needed medications. The contracts with Hope and Help Center of Central F...

PhaseBio Appoints Caroline M. Loewy to Board of Directors

MALVERN, Pa., July 19, 2018 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies for orphan diseases with an initial focus on cardiopulmonary disorders, today announced the appointment of Caroline M. Loewy to its board of directors. Ms. Loewy will serve as Chair of the Audit Committee. “Caroline has extensive ...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks